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Summary Current standard adjuvant therapies for early breast cancer include tamoxifen and chemotherapy, depending on the disease
prognosis and menopausal status. Luteinizing hormone-releasing hormone (LHRH) analogues offer a different approach to the management
of early breast cancer in pre- and perimenopausal women. The most widely studied LHRH analogue is goserelin. It acts on the
hypothalamic-pituitary axis to suppress ovarian function, decreasing luteinizing hormone and oestradiol levels to post-menopausal values.
Pooled data from 228 premenopausal and perimenopausal patients with advanced breast cancer enrolled in 29 studies worldwide
demonstrated an objective response rate for goserelin, 3.6 mg, of 36.4%, with a median duration of response of 44 weeks. These results fall
well within the ranges of reported response rates for ovarian ablation and for tamoxifen in similar patient populations. By virtue of its mode of
action, goserelin does not stimulate the ovaries and is unlikely to have detrimental effects on the endometrium. In addition, given that
goserelin has no oestrogen agonist-like effects, unlike tamoxifen, there is no potential for tumour stimulation in those patients becoming
resistant to treatment. Goserelin is generally well tolerated, and the main side-effects are related to ovarian suppression, which is potentially
reversible. Preliminary results in premenopausal women with early breast cancer indicate that endocrine treatment with goserelin plus
tamoxifen may be as effective as standard combination chemotherapy (cyclophosphamide-methotrexate-5-fluorouracil), but has significantly
less acute toxicity. A number of large, randomized trials are now in progress to assess the potential role of goserelin as adjuvant therapy for
early breast cancer.
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Current standard adjuvant therapies for early breast cancer include
tamoxifen and chemotherapy, depending on the patient's disease
prognosis and menopausal status. Tamoxifen is the established adju-
vant treatment in the post-menopausal setting. Several large trials,
however, have also shown beneficial effects with oestrogen
blockade in younger patients (< 50 years of age) (Cancer Research
Campaign Breast Cancer Trials Group, 1992; Stewart, 1992; Fisher
et al, 1996). The Early Breast Cancer Trialists' Collaborative Group
concluded that although tamoxifen may be more effective in women
aged 50 years or older, younger patients may also have a significant
reduction in disease recurrence (and mortality) compared with
controls (Early Breast Cancer Trialists' Collaborative Group, 1992).
Chemotherapy is usually the first treatment of choice in
premenopausal patients who are unlikely to respond to endocrine
therapy, such as those with oestrogen receptor (ER)-negative
tumours and/or lymph node-positive disease (Harris et al, 1992). A
comprehensive meta-analysis in 1992 revealed that chemotherapy
prolongs both disease-free and overall survival rates in
premenopausal women with early breast cancer (Early Breast
Cancer Trialists' Collaborative Group, 1992). The combination of
cyclophosphamide, methotrexate and 5-fluorouracil (CMF) was
the most widely used combination regimen, and was undoubtedly
more effective than single-agent chemotherapy at that time.
Evidence is now emerging that anthracycline-based therapies may
be superior to CMF in this patient population (Browne et al, 1996;
Coombes et al, 1996; Misset et al, 1996).
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Luteinizing hormone-releasing hormone (LHRH) analogues
offer a different approach to the management of breast cancer in
premenopausal women. Goserelin has been available for the treat-
ment of advanced breast cancer in premenopausal and peri-
menopausal women since the early 1990s, and is the most
extensively studied LHRH analogue in this setting. Sufficient
experience has now been gained, and the results are sufficiently
promising, for LHRH analogues to be considered in the treatment
of early breast cancer in premenopausal women. This paper
provides a brief review of the mechanism of action of goserelin
and its potential benefits in early breast cancer.
MODE OF ACTION OF GOSERELIN
Goserelin acts on the hypothalamic-pituitary axis, achieving
ovarian suppression by receptor down-regulation. Under physio-
logical conditions, LHRH binds to a proportion of the LHRH
receptors on the surface of pituitary cells. The occupied receptors
form clusters and pass through the cell surface into the cell itself.
As not all receptors are occupied by the pulse of LHRH, and
because there is constant receptor resynthesis, pituitary cells can
respond to a subsequent LHRH stimulus (Clayton and Catt, 1981).
Administration of goserelin initially leads to occupation of a high
proportion of LHRH receptors (Figure 1). After a single dose,
there is a short-lived rise in serum LH concentration, resulting in
increased oestradiol production by the ovaries (Thomas et al,
1986). The occupied LHRH receptors again form clusters and








Figure 1 Mode of action of goserelin. (A) Hypersecretion of LH following
acute administration of goserelin; (B) hyposecretion of LH after chronic
administration of goserelin
goserelin prevents the reappearance of receptors in sufficient
numbers to stimulate the synthesis and secretion of LH, which
falls to low levels (Figure 2) (West and Baird, 1987). This
profound suppression of LH results in a decline in oestradiol to
post-menopausal concentrations within approximately 21 days,
and these levels are maintained with continued administration of
the drug (Figure 3) (West and Baird, 1987). This decrease is,
however, potentially reversible, and normal ovarian function may
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Figure 2 Effect of chronic administration of goserelin ('Zoladex') on LH
levels in seven female volunteers. Reproduced with permission from Clinical
Endocrinology (West and Baird, 1987)
EFFICACY OF GOSERELIN IN ADVANCED
DISEASE
Evidence from its use in advanced disease suggests that goserelin
satisfies the requirements for use in the adjuvant setting. A total
of 29 studies, assessing efficacy and/or safety, have now been
performed worldwide in a large, coordinated clinical trials
programme (Blamey et al, 1992, 1993). In the 228 evaluable
patients enrolled in these open studies, the objective response rate
was 36.4%, with a median response duration of 44 weeks. These
results fall well within the range of the reported response rates for
both conventional ovarian ablation and tamoxifen in similar patient
populations (Blamey et al, 1992). In addition, responses to
goserelin, 3.6 mg, were achieved irrespective ofpatient age, tumour
grade, ER status, previous hormone therapy ordisease site, although
higher response rates were seen in patients with ER-positive and/or
well-differentiated tumours. In a randomized study of goserelin,
3.6 mg, with or without tamoxifen in premenopausal and peri-
menopausal women with locally advanced or metastatic breast
cancer, 31% ofgoserelin-treated and 38% ofgoserelin plus tamox-
ifen-treated patients had achieved an objective response at a median
of93 weeks offollow-up (Jonat et al, 1995). There was a significant
benefit in favour ofcombination therapy in time to progression (23
weeks vs 28 weeks; P = 0.03), but not in survival, at a median
follow-up of 117.5 weeks (127 weeks vs 140 weeks; P = 0.25).
POTENTIAL BENEFITS OF LHRH ANALOGUES IN
EARLY BREAST CANCER
Goserelin has a number of potential benefits as adjuvant therapy
for early breast cancer compared with other standard treatment
options in premenopausal women. Tamoxifen has several disad-
vantages when used as adjuvant therapy in this patient population.
For example, tamoxifen is known to have a stimulatory effect on
the ovaries in premenopausal women, possibly by action at the
hypothalamic-pituitary axis to block the negative feedback regula-
tion of oestrogens, and has been shown to result in supraphysio-
logical levels of oestradiol and/or ovarian cysts in certain patients
(Boccardo et al, 1994; Ravdin, 1996). In addition, tamoxifen can
act as a partial oestrogen agonist in some tissues (Jordan, 1993),
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CONCLUSIONS
The role of LHRH analogues such as goserelin in the adjuvant
and this may be associated with detrimental effects on the treatment ofearly breast cancer in premenopausal women remains
endometrium (Barakat, 1996) and sometimes on the tumour itself to be defined. The available data indicate the potential efficacy of
by tumour stimulation as tamoxifen resistance develops (DeFriend goserelin in this patient population, and it is known to be a well-
and Howell, 1994). Because of its mode of action and lack of tolerated, convenient agent. In addition, the ovarian suppressive
agonist activity beyond the initial first few days of treatment, effects are potentially reversible, which is important in the
goserelin does not stimulate the ovaries (Jordan, 1996), and is adjuvant setting. A number of large, randomized trials have now
unlikely to have a stimulatory effect on the endometrium. It is, in completed recruitment and the results will be reported over the
fact, also indicated for the treatment of a wide range of benign next 12-18 months. These results will determine the role ofLHRH
gynaecological conditions, in which suppression of the analogues as a viable treatment option for adjuvant therapy in
endometrium is required. premenopausal women with early disease.
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